Parriott Andrea, Kahn James G, Ashki Haleh, Readhead Adam, Barry Pennan M, Goodell Alex J, Flood Jennifer, Shete Priya B
8785 Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA.
8785 Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Public Health Rep. 2020 Jul/Aug;135(1_suppl):172S-181S. doi: 10.1177/0033354920927845.
Targeted testing and treatment of persons with latent tuberculosis infection (LTBI) is a critical component of the US tuberculosis (TB) elimination strategy. In January 2016, the California Department of Public Health issued a tool and user guide for TB risk assessment (California tool) and guidance for LTBI testing, and in September 2016, the US Preventive Services Task Force (USPSTF) issued recommendations for LTBI testing in primary care settings. We estimated the epidemiologic effect of adherence to both recommendations in California.
We used an individual-based Markov micro-simulation model to estimate the number of cases of TB disease expected through 2026 with baseline LTBI strategies compared with implementation of the USPSTF or California tool guidance. We estimated the risk of LTBI by age and country of origin, the probability of being in a targeted population, and the probability of presenting for primary care based on available data. We assumed 100% adherence to testing guidance but imperfect adherence to treatment.
Implementation of USPSTF and California tool guidance would result in nearly identical numbers of tests administered and cases of TB disease prevented. Perfect adherence to either recommendation would result in approximately 7000 cases of TB disease averted (40% reduction compared with baseline) by 2026. Almost all of this decline would be driven by a reduction in the number of cases among non-US-born persons.
By focusing on the non-US-born population, adherence to LTBI testing strategies recommended by the USPSTF and the California tool could substantially reduce the burden of TB disease in California in the next decade.
对潜伏性结核感染(LTBI)患者进行针对性检测和治疗是美国结核病消除战略的关键组成部分。2016年1月,加利福尼亚州公共卫生部发布了结核病风险评估工具及用户指南(加利福尼亚工具)以及LTBI检测指南,2016年9月,美国预防服务工作组(USPSTF)发布了初级保健机构LTBI检测建议。我们估计了在加利福尼亚州遵循这两项建议的流行病学效果。
我们使用基于个体的马尔可夫微观模拟模型,估计与实施USPSTF或加利福尼亚工具指南相比,采用基线LTBI策略到2026年预计的结核病病例数。我们根据现有数据估计了按年龄和原籍国划分的LTBI风险、处于目标人群的概率以及寻求初级保健的概率。我们假设对检测指南的遵循率为100%,但对治疗的遵循率不完全。
实施USPSTF和加利福尼亚工具指南将导致实施的检测数量和预防的结核病病例数几乎相同。完全遵循任何一项建议到2026年将避免约7000例结核病病例(与基线相比减少40%)。几乎所有的下降都是由非美国出生人群中的病例数减少推动的。
通过关注非美国出生人群,遵循USPSTF和加利福尼亚工具推荐的LTBI检测策略可在未来十年大幅减轻加利福尼亚州的结核病负担。